Mizui Masayuki, Tsokos George C
Department of Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, CLS-937, Boston, MA, 02215, USA.
Curr Rheumatol Rep. 2016 Nov;18(11):68. doi: 10.1007/s11926-016-0617-5.
Recent extensive research on interleukin-2 (IL-2)/IL-2 receptor (IL-2R) biology has revealed its critical role in the regulation of immune tolerance by influencing regulatory T (Treg) cell functions and survival. Since in vivo low-dose IL-2 administration in humans has been confirmed to be safe and effective in expanding Treg, it is likely that it may be considered for the treatment of several autoimmune diseases including systemic lupus erythematousus (SLE). A recent clinical trial demonstrated the safety and efficacy of low-dose IL-2 treatment on SLE. In SLE, T cells show aberrant function such as deficient IL-2 production and abnormal signaling events. Expansion of Treg by IL-2 represents a specific strategy to control self-tolerance; however, restoration of abnormal immune function and responses should be addressed more carefully in patients with SLE considering the complexity of disease etiology and pathogenesis.
近期关于白细胞介素-2（IL-2）/白细胞介素-2受体（IL-2R）生物学的广泛研究表明，它通过影响调节性T（Treg）细胞功能和存活在免疫耐受调节中发挥关键作用。由于已证实人体体内低剂量IL-2给药在扩增Treg方面安全有效，因此有可能将其考虑用于治疗包括系统性红斑狼疮（SLE）在内的多种自身免疫性疾病。最近一项临床试验证明了低剂量IL-2治疗SLE的安全性和有效性。在SLE中，T细胞表现出异常功能，如IL-2产生不足和信号转导事件异常。IL-2扩增Treg是控制自身耐受的一种特定策略；然而，考虑到疾病病因和发病机制的复杂性，对于SLE患者，应更谨慎地处理异常免疫功能和反应的恢复问题。
